{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-22-000123","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2022-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.357166+00:00","generated_at":"2026-06-21T16:41:47.626576+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Summit Therapeutics appoints Dr. Alessandra Cesano to Board of Directors, effective immediately","bullets":["Dr. Cesano brings 25 years of oncology R&D experience; previously CMO at ESSA Pharma, NanoString, and Cleave Biosciences.","She played an instrumental role in development and approval of Vectibix® (panitumumab) for colorectal cancer.","Appointment aligns with Summit's plan to expand pipeline into oncology; she joins Compensation and Nominating Committees.","Dr. Cesano also serves on the board of Puma Biotechnology (NASDAQ: PBYI) and is independent under Nasdaq rules."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-22-000123","json":"https://secwatch.observer/filing/0001599298-22-000123.json","markdown":"https://secwatch.observer/filing/0001599298-22-000123.md","text":"https://secwatch.observer/filing/0001599298-22-000123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929822000123/0001599298-22-000123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929822000123/smmt-20221115.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T16:41:47.626576+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"320f4d2a19","claim":"Dr. Alessandra Cesano was elected as Director at Summit Therapeutics Inc..","evidence_excerpt":"Effective on November 15, 2022, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) unanimously approved (i) the election of Dr. Alessandra Cesano, MD, PhD as a director of the Company and (ii) the appointment of Dr. Cesano to serve on the Compensation Committee and the Nominating and Corporate Governance Committee of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929822000123/0001599298-22-000123-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}